Shares of Asian drugmakers drop after Trump threatens tariffs

Asian drugmaker shares mostly fell following U.S. President Trump's threat of 100% tariffs on branded pharmaceutical imports from October 1 for producers lacking U.S. manufacturing plants. Key declines included Samsung Biologics (-1.6%) and Sumitomo Pharma (-4.3%), though Celltrion gained 1.3% after a U.S. acquisition. Analysts suggest these sectoral tariffs signal a persistent trend, potentially elevating the global effective tariff rate to 18%, despite limited broader economic impact on some Asian nations.

Analysis

A U.S. threat to impose 100% tariffs on imported branded pharmaceuticals has triggered a significant, yet differentiated, market reaction among Asian drugmakers. Companies perceived as exposed saw notable declines, with Samsung Biologics falling 1.6%, Sumitomo Pharma tumbling 4.3%, and the Hang Seng Biotech Index dropping 2.58%. In contrast, Celltrion rose 1.3% after announcing a $330 million acquisition of a U.S.-based entity from Eli Lilly, suggesting the market is rewarding firms that are proactively establishing a U.S. presence to circumvent potential tariffs. This divergence is reinforced by modest gains in Takeda (+0.2%) and Shionogi (+1.3%), indicating the market is not uniformly bearish. Expert commentary suggests these sectoral tariffs are legally sound and likely to persist, potentially raising the global effective tariff rate from approximately 10% to 18%, framing this as a structural shift in trade policy rather than a temporary negotiating tactic. However, the broader macroeconomic impact on economies like Japan is expected to be limited, concentrating the risk within the pharmaceutical sector itself.

Key Decisions for Investors

• Investors should re-evaluate holdings in Asian pharmaceutical companies, discriminating between those with a U.S. manufacturing footprint and those without, as the latter face significant downside risk from the threatened 100% tariffs.
• Consider that strategic M&A to establish a U.S. presence, as demonstrated by Celltrion, is being viewed as a key de-risking catalyst and may unlock value for companies pursuing this strategy.
• Treat the implementation of sectoral tariffs as a persistent structural risk for the global pharmaceutical supply chain, not a transient political headline, and adjust long-term sector exposure accordingly.
• Investigate the specific business characteristics of resilient stocks like Takeda and Shionogi to identify potential defensive positions or relative value opportunities within a broadly impacted sector.